Although it would seem to make sense that routine glucose self-monitoring provides better outcomes, this long-held belief is not supported by the data, said an editor's note accompanying the study.
Results from the Diabetes Prevention Program Outcomes Study also showed that metformin was cost-effective compared to placebo for patients at high risk of diabetes.
The observational analysis compared sodium-glucose co-transporter-2 (SGLT2) inhibitors with other glucose-lowering drugs in patients with type 2 diabetes in Denmark, Norway, and Sweden.
Patients with type 1 diabetes taking dapagliflozin for 24 weeks had lower HbA1c level, body weight, and insulin dose than those on placebo, according to the industry-funded study.
The industry-funded study used international data to compare rates of heart failure hospitalization and mortality in patients on sodium glucose cotransporter-2 (SGLT2) inhibitors or other glucose-lowering drugs.
In addition to approved drugs duloxetine, pregabalin, and tapentadol, some benefits were found with venlafaxine, oxcarbazepine, tricyclic antidepressants, tramadol, and botulinum toxin.
In adults with uncontrolled type 2 diabetes who initially declined insulin versus those who initially accepted, median time to an HbA1c level below 7.0% was 50 months versus 38 months.
A retrospective study of Canadian and British patients with type 2 diabetes found lower rates of cardiovascular death among those taking sodium-glucose cotransporter-2 (SGLT-2) inhibitors than in matched patients who took dipeptidyl peptidase-4
The frequency of diabetes visits varied across health systems, but within most of the studied organizations, patients with high HbA1c levels were not seen any more often than those with lower levels.
The results highlight the heterogeneity of type 2 diabetes and may help explain the differences in disease progression and response to glucose-lowering treatment seen in clinical practice, an accompanying comment